X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (196) 196
male (136) 136
female (132) 132
aged (126) 126
middle aged (126) 126
index medicus (120) 120
oncology (119) 119
chemotherapy (83) 83
adult (75) 75
cancer (67) 67
gemcitabine (59) 59
deoxycytidine - analogs & derivatives (53) 53
treatment outcome (52) 52
pancreatic cancer (48) 48
antineoplastic combined chemotherapy protocols - therapeutic use (45) 45
gastroenterology & hepatology (45) 45
pancreatic neoplasms - drug therapy (45) 45
medicine & public health (43) 43
hepatocellular carcinoma (42) 42
surgery (41) 41
survival (40) 40
japan (39) 39
aged, 80 and over (38) 38
prognosis (38) 38
clinical trials (33) 33
deoxycytidine - administration & dosage (33) 33
pancreatic neoplasms - pathology (32) 32
research (32) 32
s-1 (32) 32
5-fluorouracil (31) 31
cisplatin (31) 31
survival rate (31) 31
carcinoma (30) 30
therapy (30) 30
antineoplastic agents - therapeutic use (29) 29
trial (29) 29
drug combinations (28) 28
biliary tract cancer (27) 27
care and treatment (27) 27
survival analysis (27) 27
biliary tract neoplasms - drug therapy (25) 25
disease-free survival (25) 25
liver cancer (24) 24
pharmacology & pharmacy (24) 24
retrospective studies (24) 24
sorafenib (24) 24
tegafur - administration & dosage (24) 24
neoplasm staging (23) 23
patients (23) 23
antineoplastic combined chemotherapy protocols - adverse effects (22) 22
deoxycytidine - therapeutic use (22) 22
liver neoplasms - drug therapy (22) 22
antineoplastic agents (21) 21
carcinoma, hepatocellular - drug therapy (21) 21
liver neoplasms - pathology (21) 21
oxonic acid - administration & dosage (21) 21
surgical oncology (21) 21
deoxycytidine - adverse effects (20) 20
metastasis (20) 20
analysis (19) 19
antimitotic agents (19) 19
electricity (19) 19
gastroenterology (19) 19
pathology (19) 19
pharmacology/toxicology (19) 19
carcinoma, hepatocellular - pathology (18) 18
medical colleges (18) 18
optics (18) 18
adenocarcinoma (17) 17
antimetabolites, antineoplastic - therapeutic use (17) 17
basic electric elements (17) 17
carcinoma, hepatocellular - therapy (17) 17
combination (17) 17
hepatoma (17) 17
liver neoplasms - therapy (17) 17
pancreatic neoplasms - mortality (17) 17
tumors (17) 17
abdominal surgery (16) 16
devices using stimulated emission (16) 16
antineoplastic agents - adverse effects (15) 15
cancer research (15) 15
drug administration schedule (15) 15
medical prognosis (15) 15
oncology, experimental (15) 15
phase-ii (15) 15
radiotherapy (15) 15
antimetabolites, antineoplastic - administration & dosage (14) 14
antimetabolites, antineoplastic - adverse effects (14) 14
cancer therapies (14) 14
clinical trials as topic (14) 14
diagnostic radiology (14) 14
drug therapy (14) 14
multicenter (14) 14
risk factors (14) 14
solid tumors (14) 14
tegafur - adverse effects (14) 14
adenocarcinoma - drug therapy (13) 13
adenocarcinoma - pathology (13) 13
cisplatin - administration & dosage (13) 13
combined modality therapy (13) 13
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pancreatology, ISSN 1424-3903, 09/2017, Volume 17, Issue 4, pp. S11 - S11
Conclusion: We conducted a randomized phase II trial of chemoradiotherapy using S-1 with or without induction chemotherapy using gemcitabine for LAPC... 
Clinical trials | Chemotherapy | Toxicity | Pancreatic cancer | Medical prognosis
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2015, Volume 26, Issue suppl 7, pp. vii9.5 - vii10
Journal Article
JOURNAL OF CLINICAL MEDICINE, ISSN 2077-0383, 08/2019, Volume 8, Issue 8, p. 1170
Systemic chemotherapy plays an important role in the treatment of pancreatic cancer, to improve the survival of patients with pancreatic cancer. Unresectable... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | PLUS S-1 | second-line chemotherapy | locally advanced pancreatic cancer | hereditary pancreatic cancer | OXALIPLATIN | MODIFIED-FOLFIRINOX | FOLINIC ACID | metastatic pancreatic cancer | GEMCITABINE
Journal Article
Journal of Hepato‐Biliary‐Pancreatic Sciences, ISSN 1868-6974, 05/2018, Volume 25, Issue 5, pp. 261 - 268
While surgery currently remains the only potentially curative treatment available for pancreatic cancer, only 20% to 30% of patients have resectable disease at... 
Distant metastasis | Surgical resection | Chemotherapy | Pancreatic cancer | ADJUVANT CHEMOTHERAPY | SURGERY | FOLFIRINOX | DUCTAL ADENOCARCINOMA | RESECTION | LONG-TERM SURVIVAL | CHEMORADIOTHERAPY | PHASE-III TRIAL | ERLOTINIB PLUS GEMCITABINE | THERAPY | NAIVE JAPANESE PATIENTS | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article
Cancer Science, ISSN 1347-9032, 09/2014, Volume 105, Issue 9, pp. 1176 - 1181
This study analyzed outcomes of systemic chemotherapy for advanced neuroendocrine carcinoma ( NEC ) of the digestive system. Clinical data from 258 patients... 
neuroendocrine carcinoma | digestive system | etoposide | irinotecan | Cisplatin | Etoposide | Irinotecan | Digestive system | Neuroendocrine carcinoma | DIAGNOSIS | ETOPOSIDE/CISPLATIN | MANAGEMENT | CELL LUNG-CANCER | PHASE-III TRIAL | CONSENSUS GUIDELINES | IRINOTECAN/CISPLATIN | ONCOLOGY | EXPERIENCE | Leucovorin - administration & dosage | Prognosis | Gastrointestinal Neoplasms - drug therapy | Gastrointestinal Neoplasms - mortality | Humans | Male | Cisplatin - administration & dosage | Gastrointestinal Neoplasms - pathology | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Camptothecin - administration & dosage | Female | Retrospective Studies | Camptothecin - analogs & derivatives | Carcinoma, Neuroendocrine - mortality | Carcinoma, Neuroendocrine - drug therapy | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proportional Hazards Models | Carboplatin - administration & dosage | Etoposide - administration & dosage | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Neuroendocrine - pathology | Deoxycytidine - analogs & derivatives | Antimitotic agents | Chemotherapy | Carcinoma | Analysis | Gastrointestinal system | Antineoplastic agents | Cancer | Dehydrogenases | Clinical trials | Multivariate analysis | Intestine | Pancreas | Stomach | Medical research | Research & development--R&D | Histology | Gastrointestinal tract | Survival | Patients | L-Lactate dehydrogenase | Esophagus | Medicine | Hospitals | Medical prognosis | Lactic acid | Neuroendocrine tumors | Pharmaceuticals | Original
Journal Article
Japanese Journal of Cancer and Chemotherapy, ISSN 0385-0684, 10/2017, Volume 44, Issue 10, pp. 827 - 830
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 10/2017, Volume 44, Issue 10, p. 827
Pancreatic cancer, adenocarcinoma, generally rapidly progresses, and if a metastatic lesion is detected, chemotherapy is applied even in solitary metastasis.... 
Neoplasm Metastasis | Prognosis | Pancreatic Neoplasms - diagnosis | Humans | Pancreatic Neoplasms - pathology | Pancreatic Neoplasms - therapy
Journal Article
Journal Article
Journal Article
Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, ISSN 0446-6586, 2017, Volume 114, Issue 4, p. 637
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 10/2016, Volume 51, Issue 10, pp. 1011 - 1021
Sorafenib was approved for treatment of unresectable hepatocellular carcinoma (HCC) in Japan in 2009. A prospective postmarketing all-patient surveillance... 
Molecular targeted therapy | Medicine & Public Health | Postmarketing surveillance | Colorectal Surgery | Hepatology | Sorafenib | Gastroenterology | Abdominal Surgery | Hepatocellular carcinoma | Surgical Oncology | Japanese | ACTIVATION | SCORE | MANAGEMENT | PROGNOSTIC-FACTORS | EFFICACY | ANGIOGENESIS | PHASE-III TRIAL | LIVER-CANCER | THERAPY | FIELD PRACTICE | GASTROENTEROLOGY & HEPATOLOGY | Niacinamide - analogs & derivatives | Prospective Studies | Follow-Up Studies | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hand-Foot Syndrome - etiology | Diarrhea - chemically induced | Young Adult | Carcinoma, Hepatocellular - drug therapy | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Hypertension - chemically induced | Aged, 80 and over | Product Surveillance, Postmarketing | Adult | Female | Liver Neoplasms - pathology | Child | Chemical and Drug Induced Liver Injury - etiology | Japan | Liver Neoplasms - drug therapy | Niacinamide - adverse effects | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Survival Rate | Withholding Treatment | Disease Progression | Patient Acuity | Adolescent | Carcinoma, Hepatocellular - pathology | Sex Factors | Aged | Neoplasm Staging | Antimitotic agents | Medicine | Medical research | Safety and security measures | Liver diseases | Analysis | Medicine, Experimental | Hemoglobin | Practice | Hepatoma | Hepatitis C | Antineoplastic agents | Original —Liver, Pancreas, and Biliary Tract
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 02/2016, Volume 43, Issue 2, p. 160
Journal Article
Gan to kagaku ryoho. Cancer & chemotherapy, ISSN 0385-0684, 02/2016, Volume 43, Issue 2, pp. 160 - 164
Journal Article
Journal of Gastroenterology, ISSN 0944-1174, 12/2016, Volume 51, Issue 12, pp. 1150 - 1160
Journal Article